据报道,罗氏、礼来和阿斯利康等制药巨头公开表示反对诺和诺德收购合同药品生产商康泰伦特,称这将限制减肥药领域的竞争,不利于行业发展。
减肥药行业一直处于快速发展阶段,康泰伦特作为多家公司的合同生产商,扮演着重要角色。一旦被诺和诺德收购,可能削弱其他公司在减肥药生产和供应方面的竞争力,引发行业担忧。
值得注意的是,在此背景下,肥胖症药物研发公司Viking Therapeutics的股价当日夜盘大涨5.17%。分析人士认为,如果诺和诺德的收购案被阻挡,有利于维护减肥药行业的竞争环境,从而对Viking Therapeutics等公司的长远发展形成利好影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.